SevenBridge Financial Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

SevenBridge Financial Group’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-200	Closed	-$3K	–	619
2018 Q3	$3K	Hold	200	–	–	﹤0.01%	541
2018 Q2	$3K	Hold	200	–	–	﹤0.01%	543
2018 Q1	$3K	Hold	200	–	–	﹤0.01%	560
2017 Q4	$4K	Hold	200	–	–	﹤0.01%	546
2017 Q3	$8K	Hold	200	–	–	﹤0.01%	475
2017 Q2	$6K	Hold	200	–	–	﹤0.01%	506
2017 Q1	$7K	Hold	200	–	–	﹤0.01%	475
2016 Q4	$10K	Hold	200	–	–	0.01%	445
2016 Q3	$10K	Hold	200	–	–	0.01%	440
2016 Q2	$8K	Buy	+200	New	+$8.7K	0.01%	547

Other funds holding FPRX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SevenBridge Financial Group's FPRX Position: Q4 2018 in Review

SevenBridge Financial Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2018, closing a stake of 200 shares — an estimated $3K sold.

SevenBridge Financial Group first reported a position in FPRX in Q2 2016 and held it in 10 quarters. The position peaked at $10K in Q4 2016. 116 funds tracked by Wall St. Rank hold FPRX as of Q4 2018.

SevenBridge Financial Group reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
SevenBridge Financial Group sold 200 Five Prime Therapeutics, Inc. shares in Q4 2018, an estimated $3K.
SevenBridge Financial Group first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 10 quarters.
SevenBridge Financial Group's Five Prime Therapeutics, Inc. position peaked at $10K in Q4 2016.
116 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2018.

Based on SevenBridge Financial Group's 13F filing for Q4 2018, filed 14 Feb 2019.